3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Hematologic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Interventions
Dexamethasone
8
daratumumab
5
Lenalidomide
5
Bortezomib
5
Thalidomide
4
Cyclophosphamide
4
carfilzomib
2
Melphalan
2
Calcium Dobesilate
2
trametinib
1
tanespimycin
1
pomalidomide
1
fludarabine
1
dabrafenib
1
cobimetinib
1
Whole-Body Irradiation
1
Vemurafenib
1
Stem Cell Transplantation
1
Rivaroxaban
1
Mesna
1
MAGEA3 protein, human
1
Lenograstim
1
Human Growth Hormone
1
Hematopoietic Stem Cell Transplantation
1
Granulocyte Colony-Stimulating Factor
1
Etoposide
1
Busulfan
1
Bone Marrow Transplantation
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Multiple Myeloma
×
Vemurafenib
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled